Determination of whether HIPEC is beneficial in patients with synchronous peritoneal and liver metastases from colorectal cancer (Review)
- Authors:
- Nicolae Bacalbasa
- Irina Balescu
- Dragos Cretoiu
- Ioana Halmaciu
- Mihai Dimitriu
- Bogdan Socea
- Camelia Diaconu
- Laura Iliescu
- Cornel Savu
- Carmen Savu
- Alexandru Filipescu
- Claudia Stoica
- Ovidiu Stiru
-
Affiliations: Department of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Visceral Surgery, ‘Ponderas’ Academic Hospital, 021188 Bucharest, Romania, Department of Cellular, Molecular and Histology Biology, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Anatomy, ‘George Emil Palade’ University of Medicine, Pharmacy, Science and Technology, 540142 Târgu Mureș, Romania, Department of Surgery, ‘Sf. Pantelimon’ Emergency Clinical Hospital, 021659 Bucharest, Romania, Department of Internal Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Thoracic Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania, Department of Anesthesiology, ‘Fundeni’ Clinical Institute, 022328 Bucharest, Romania, Department of Visceral Surgery, County Emergency Hospital Ilfov, 022104 Bucharest, Romania, Department of Cardiovascular Surgery, ‘Carol Davila’ University of Medicine and Pharmacy, 020021 Bucharest, Romania - Published online on: September 7, 2021 https://doi.org/10.3892/etm.2021.10702
- Article Number: 1267
This article is mentioned in:
Abstract
Sammartino P, Sibio S, Biacchi D, Cardi M, Mingazzini P, Rosati MS, Cornali T, Sollazzo B, Atta JM and Di Giorgio A: Long-term results after proactive management for locoregional control in patients with colonic cancer at high risk of peritoneal metastases. Int J Colorectal Dis. 29:1081–1089. 2014.PubMed/NCBI View Article : Google Scholar | |
Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 7:69–76. 2006.PubMed/NCBI View Article : Google Scholar | |
Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M and Hesdorffer M: Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 12:928–935. 2016.PubMed/NCBI View Article : Google Scholar | |
Sugarbaker PH and Kwong ML: Regional chemotherapy: Possibilities for prevention and treatment of peritoneal metastases from gastric cancer. In: Management of Gastric cancer. SMGroup. https://smjournals.com/ebooks/management-of-gastric-cancer/chapters/MGC-16-05.pdf. Access date? | |
Sugarbaker PH: Prevention and treatment of peritoneal metastases: A comprehensive review. Indian J Surg Oncol. 10:3–23. 2019.PubMed/NCBI View Article : Google Scholar | |
Pestieau SR and Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant vs delayed management. Dis Colon Rectum. 43:1341–1348. 2000.PubMed/NCBI View Article : Google Scholar | |
Tentes AA, Spiliotis ID, Korakianitis OS, Vaxevanidou A and Kyziridis D: Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: Preliminary results. ISRN Surg. 2011(529876)2011.PubMed/NCBI View Article : Google Scholar | |
Noura S, Ohue M, Shingai T, Kano S, Ohigashi H, Yano M, Ishikawa O, Takenaka A, Murata K and Kameyama M: Effects of intraperitoneal chemotherapy with mitomycin C on the prevention of peritoneal recurrence in colorectal cancer patients with positive peritoneal lavage cytology findings. Ann Surg Oncol. 18:396–404. 2011.PubMed/NCBI View Article : Google Scholar | |
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 22:3284–3292. 2004.PubMed/NCBI View Article : Google Scholar | |
Sugarbaker PH, van der Speeten K, Stuart OA, Chang D and Mahteme H: Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Cytoreductive Surgery and Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. Sugarbaker PH (ed). Cine-Med Publishing, Woodbury, NY, pp183-206, 2012. | |
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H and Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 21:3737–3743. 2003.PubMed/NCBI View Article : Google Scholar | |
Verwaal VJ, Bruin S, Boot H, van Slooten G and van Tinteren H: 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 15:2426–2432. 2008.PubMed/NCBI View Article : Google Scholar | |
Elias D, Benizri E, Pocard M, Ducreux M, Boige V and Lasser P: Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol. 32:632–636. 2006.PubMed/NCBI View Article : Google Scholar | |
de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA and Te Velde EA: Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 39:321–327. 2013.PubMed/NCBI View Article : Google Scholar | |
Tan GH, Teo MC, Chen W, Lee SY, Ng DW, Tham CK and Soo KC: Surgical management of colorectal peritoneal metastases: Treatment and outcomes compared with hepatic metastases. J Gastrointest Cancer. 44:170–176. 2013.PubMed/NCBI View Article : Google Scholar | |
Abreu de Carvalho LF, Scuderi V, Maes H, Cupo P, Geerts B, Van Bockstal M, Gremonprez F, Willaert W, Pattyn P, Troisi R, et al: Simultaneous parenchyma-preserving liver resection, cytoreductive surgery and intraperitoneal chemotherapy for stage IV colorectal cancer. Acta Chir Belg. 115:261–267. 2015.PubMed/NCBI View Article : Google Scholar | |
Alzahrani N, Ung L, Valle SJ, Liauw W and Morris DL: Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: Results from an Australian centre. ANZ J Surg. 87:E167–E172. 2017.PubMed/NCBI View Article : Google Scholar | |
Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, Virzi S, Mazzaferro V and Deraco M: Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 61:1026–1034. 2018.PubMed/NCBI View Article : Google Scholar | |
Lorimier G, Linot B, Paillocher N, Dupoiron D, Verriele V, Wernert R, Hamy A and Capitain O: Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 43:150–158. 2017.PubMed/NCBI View Article : Google Scholar | |
Navez J, Remue C, Leonard D, Bachmann R, Kartheuser A, Hubert C, Coubeau L, Komuta M, Van den Eynde M, Zech F and Jabbour N: Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Report from a single-centre experience. Ann Surg Oncol. 23 (Suppl 5):S666–S673. 2016.PubMed/NCBI View Article : Google Scholar | |
Delhorme JB, Dupont-Kazma L, Addeo P, Lefebvre F, Triki E, Romain B, Meyer N, Bachellier P, Rohr S and Brigand C: Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery? Int J Surg. 25:98–105. 2016.PubMed/NCBI View Article : Google Scholar | |
Jeon Y, Park EJ, Lim JH and Baik SH: Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer. World J Surg Oncol. 17(214)2019.PubMed/NCBI View Article : Google Scholar | |
Pinto A, Hobeika C, Philis A, Kirzin S, Carrere N and Ghouti L: Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: Different strategies for curative treatment? Langenbecks Arch Surg. 404:477–488. 2019.PubMed/NCBI View Article : Google Scholar | |
Soldevila-Verdeguer C, Segura-Sampedro JJ, Pineno-Flores C, Sanchis-Cortes P, Gonzalez-Argente X and Morales-Soriano R: Hepatic resection and blood transfusion increase morbidity after cytoreductive surgery and HIPEC for colorectal carcinomatosis. Clin Transl Oncol. 22:2032–2039. 2020.PubMed/NCBI View Article : Google Scholar | |
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, et al: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 36 (Suppl 18)(LBA3503)2018. | |
Bakkers C, van Erning FN, Rovers KP, Nienhuijs SW, Burger JW, Lemmens VE, Aalbers AG, Kok NF, Boerma D, Brandt AR, et al: Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Eur J Surg Oncol. 46:1902–1907. 2020.PubMed/NCBI View Article : Google Scholar | |
Al Shammaa HA, Li Y and Yonemura Y: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol. 14:1159–1166. 2008.PubMed/NCBI View Article : Google Scholar | |
Jayne DG, Fook S, Loi C and Seow-Choen F: Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 89:1545–1550. 2002.PubMed/NCBI View Article : Google Scholar | |
Grundmann RT: Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg. 3:183–196. 2011.PubMed/NCBI View Article : Google Scholar | |
da Silva RG and Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 203:878–886. 2006.PubMed/NCBI View Article : Google Scholar | |
Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, Dumont F and Elias D: Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study. Ann Surg Oncol. 22:2958–2964. 2015.PubMed/NCBI View Article : Google Scholar | |
Sugarbaker PH: Pseudomyxoma peritonei and peritoneal metastases from appendiceal malignancy. In: Cytoreductive Surgery and Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas. 2nd edition. Sugarbaker PH (ed). Cine-Med Publishers, Woodbury, NY, pp109-132, 2017. | |
Hentzen JEKR, van der Plas WY, Kuipers H, Ramcharan S, Been LB, Hoogwater FJH, van Ginkel RJ, van Dam GM, Hemmer PHJ and Kruijff S: Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases. Eur J Surg Oncol. 46:590–599. 2020.PubMed/NCBI View Article : Google Scholar | |
Elias D, Mariani A, Cloutier AS, Blot F, Goere D, Dumont F, Honore C, Billard V, Dartigues P and Ducreux M: Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 40:1467–1473. 2014.PubMed/NCBI View Article : Google Scholar | |
BacalbaSa N, Balescu I, Dima S and Popescu I: The role of re-resection for breast cancer liver metastases-a single center experience. Anticancer Res. 35:6877–6880. 2015.PubMed/NCBI | |
BacalbaSa N, Balescu I, Dima S and Popescu I: Long-term survivors after liver resection for ovarian cancer liver metastases. Anticancer Res. 35:6919–6923. 2015.PubMed/NCBI | |
BacalbaSa N, Balescu I, Dima S and Popescu I: Long-term survivors after liver resection for breast cancer liver metastases. Anticancer Res. 35:6913–6917. 2015.PubMed/NCBI | |
BacalbaSa N, Dima SO, Purtan-Purnichescu R, Herlea V and Popescu I: Role of surgical treatment in breast cancer liver metastases: A single center experience. Anticancer Res. 34:5563–5568. 2014.PubMed/NCBI | |
BacalbaSa N, Dima S, Brasoveanu V, David L, Balescu I, Purnichescu-Purtan R and Popescu I: Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol. 13(235)2015.PubMed/NCBI View Article : Google Scholar | |
Bacalbasa N, Brezean I, Anghel C, Barbu I, Pautov M, Balescu I and Brasoveanu V: Successful resection and vascular ligation of a large hepatic artery aneurysm-a case report and literature review. In Vivo. 31:979–982. 2017.PubMed/NCBI View Article : Google Scholar | |
BacalbaSa N, Brezean I, Anghel C, Barbu I, Pautov M, Balescu I and Brasoveanu V: Management of a fulminant upper gastrointestinal bleeding exteriorized through hemobilia due to arteriobiliary fistula between the common bile duct and a right hepatic artery aneurysm-a case report. In Vivo. 31:983–989. 2017.PubMed/NCBI View Article : Google Scholar | |
Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M and Schlitt HJ: Treatment of colorectal liver metastases in Germany: A ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 14(810)2014.PubMed/NCBI View Article : Google Scholar | |
Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D: Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol. 27:1829–1835. 2009.PubMed/NCBI View Article : Google Scholar | |
Khrizman P and Mulcahy MF: Curative approach for stage IV colorectal cancer with multiorgan involvement: What makes sense and what doesn't? Curr Colorectal Cancer Rep. 6:97–107. 2010. | |
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of surgical oncology. Ann Surg Oncol. 14:128–133. 2007.PubMed/NCBI View Article : Google Scholar | |
Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, Quadros CA, Somashekhar SP, Ceelen W, Dube P, et al: The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the peritoneal surface oncology group international (PSOGI). Eur J Surg Oncol. 44:1942–1948. 2018.PubMed/NCBI View Article : Google Scholar | |
Steffen T, Eden J, Bijelic L, Glatzer M, Glehen O, Goéré D, de Hingh I, Li Y, Moran B, Morris D, et al: Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: Consensus on decision making among international experts. Clin Colorectal Cancer. 19:277–284. 2020.PubMed/NCBI View Article : Google Scholar | |
Vassos N and Piso P: Metastatic colorectal cancer to the peritoneum: Current treatment options. Curr Treat Options Oncol. 19(49)2018.PubMed/NCBI View Article : Google Scholar | |
Maggiori L, Goere D, Viana B, Tzanis D, Dumont F, Honore C, Eveno C and Elias D: Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg. 258:116–121. 2013.PubMed/NCBI View Article : Google Scholar | |
Downs-Canner S, Shuai Y, Ramalingam L, Pingpank JF, Holtzman MP, Zeh HJ, Bartlett DL and Choudry HA: Safety and efficacy of combined resection of colorectal peritoneal and liver metastases. J Surg Res. 219:194–201. 2017.PubMed/NCBI View Article : Google Scholar | |
Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A and Birgisson H: Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 27:293–300. 2020.PubMed/NCBI View Article : Google Scholar | |
Morgan Z, Chow BE, Strong EA, Tsai S, Christians K, Mogal H, Gamblin TC and Clarke CN: RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res. 240:130–135. 2019.PubMed/NCBI View Article : Google Scholar | |
Cascales-Campos PA, Lopez-Lopez V, Torres-Melero J, Arjona A, Munoz-Casares FC, Barrios P, Morales R, Pereira F, Bretcha-Boix P, Gonzalez-Bayon L, et al: Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): Multicenter study of the Spanish group of peritoneal cancer surgery (GECOP). Clin Transl Oncol. 22:130–136. 2020.PubMed/NCBI View Article : Google Scholar | |
Cloyd JM, Abdel-Misih S, Hays J, Dillhoff ME, Pawlik TM and Schmidt C: Impact of synchronous liver resection on the perioperative outcomes of patients undergoing CRS-HIPEC. J Gastrointest Surg. 22:1576–1584. 2018.PubMed/NCBI View Article : Google Scholar | |
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, et al: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg. 250:187–196. 2009.PubMed/NCBI View Article : Google Scholar | |
Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M and Deraco M: Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-Based HIPEC: A comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol. 27:98–106. 2020.PubMed/NCBI View Article : Google Scholar | |
Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I and Chatelut E: Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol. 62:679–683. 2008.PubMed/NCBI View Article : Google Scholar | |
Mahteme H, Wallin I, Glimelius B, Pahlman L and Ehrsson H: Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol. 64:907–911. 2008.PubMed/NCBI View Article : Google Scholar | |
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goere D and Bonastre J: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 27:681–685. 2009.PubMed/NCBI View Article : Google Scholar | |
Quenet F, Goere D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B and Elias D: Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 254:294–301. 2011.PubMed/NCBI View Article : Google Scholar | |
Wisselink DD, Braakhuis LLF, Gallo G, van Grevenstein WMU, van Dieren S, Kok NFM, de Reuver PR, Tanis PJ and de Hingh IHJT: Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol. 142:119–129. 2019.PubMed/NCBI View Article : Google Scholar | |
Hulshof EC, Lurvink RJ, Caserta N, de Hingh IHJT, van Wezel T, Bohringer S, Swen JJ, Gelderblom H, Guchelaar HJ and Deenen MJ: Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases. Eur J Surg Oncol. 46:1925–1931. 2020.PubMed/NCBI View Article : Google Scholar | |
Glockzin G, Gerken M, Lang SA, Klinkhammer-Schalke M, Piso P and Schlitt HJ: Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: A retrospective analysis. BMC Cancer. 14(807)2014.PubMed/NCBI View Article : Google Scholar | |
Hompes D, Aalbers A, Boot H, van Velthuysen ML, Vogel W, Prevoo W, van Tinteren H and Verwaal V: A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. Colorectal Dis. 16:O264–O272. 2014.PubMed/NCBI View Article : Google Scholar | |
Klaver YL, de Hingh IH, Boot H and Verwaal VJ: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy. J Surg Oncol. 103:431–434. 2011.PubMed/NCBI View Article : Google Scholar | |
Waite K and Youssef H: The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review. Ann Surg Oncol. 24:705–720. 2017.PubMed/NCBI View Article : Google Scholar | |
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E and Sarkar S: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 23:3706–3712. 2005.PubMed/NCBI View Article : Google Scholar | |
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.PubMed/NCBI View Article : Google Scholar | |
Hapani S, Chu D and Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol. 10:559–568. 2009.PubMed/NCBI View Article : Google Scholar | |
Eveno C, Passot G, Goere D, Soyer P, Gayat E, Glehen O, Elias D and Pocard M: Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 21:1792–1800. 2014.PubMed/NCBI View Article : Google Scholar |